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Single high dose rate brachytherapy boost for localized prostate adenocarcinoma
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Introduction. Brachytherapy allows administrating a highly conformed dose that is very important in prostate cancer disease
control.
Objectives. To assess outcomes of a single fraction high dose rate brachytherapy implant boost (HDR) to 3D external radiation
with image guidance (IGRT) in patients with localized prostate adenocarcinoma.
Methods. From 2009 to 2012, 25 consecutive patients with T1-2N0M0 were treated in our institution. Their median age was 67
years. In 20 patients IGRT+HDR was the primary treatment (90% RTOG’s high risk). In 5 cases the IGRT+HDR was a salvage
treatment after local failure of either previous I-125 brachytherapy (4 patients) or surgery (1 patient). Mean dose administered
was 48.7Gy (40–55.8) for external beam radiation and 11.21Gy (9.5–14) for HDR. HDR was given about 1 month after completion
of IGRT in 21 patients, in the middle of external radiation in 2 cases and before the beginning of IGRT in the other 2. The prostate
dose (IGRT and HDR) resulted in biological equivalent doses (>128Gy=3). 75% of patients also had at least 6 months of hormonal
treatment (/( (HT).
Results. All patients completed treatment. Median follow up is 7 months (range: 2–36). No RTOG greater than grade 2 toxicities
were found. Acute toxicities were: 45% and 10%. Late urinary and rectal toxicities presented in 10% and 5%. 96% of patients are
free from biochemical relapse. The only patient with biochemical relapse has bone metastases resistant to HT.
Conclusion. Single fraction HDR boost is a safe and effective method of dose escalation for newly diagnosed or relapsing localized
prostate cancer, with acceptable acute and late toxicities. A larger follow-up is necessary to assess overall and biochemical
relapse-free survival.
http://dx.doi.org/10.1016/j.rpor.2013.03.522
Stereotactic body radiation therapy (8 fractions) versus moderate hypofractionation (20 fractions) for localized
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Introduction. Acute grade 3 toxicity is uncommon during stereotactic body radiation therapy (SBRT), mainly in low-risk prostate
cancer (PCa), using robotic radiosurgery (Katz, 2010; Freeman, 2011). To our knowledge there is only one study evaluating in part
tomotherapy SBRT (Boike, 2011).
Purpose. Single-institution prospective study.
Endpoint. To describe acute GU and GI toxicity of two dose-escalation hypofractionated schemes.
Methods. Since 5-2012 thirteen patients were treated with 8 fx of 5.48–5.65Gy to 43.84–45.20Gy on alternate days (group A). In
this same period of time, 13 patients were irradiated following the same protocol but delivering 19–20 fx of 3.17Gy, 5 fx/week,
to 60.23–63.40Gy (group B). Both schemes are isoeffective for late-response tissues (a/b3): 74.3 and 78.2Gy for low risk (LR) and
intermediate-high risk (IHR). EQD2 PCa (a/b1.5): 87.4Gy (LR) and 92.3Gy (IHR) in group A; 80.3Gy (LR) and 84.6Gy (IHR) in group
B. Exclusion criteria: Gleason score ≥8, PSA>20, cT3b-4, cN1, cM1, IPSS≥20 (only group A), history of acute urinary retention.
MVCT for on-line correction was performed in every fraction. All men received neoadjuvant-concomitant ADT.
Results. Patient characteristics groups A and B: mean age=71.7 and 70.9, cT1 (53% and 43%) T2 (30% and 43%) T3a (17% and 14%),
GS6 (46% and 43%), GS7 (54% and 57%), median PSA=8.2ng and 7.9ng, LR=23% and 29% IR=54% and 57% HR=33% and 14%,
median IPSS=5 and 18. CTCAE acute GI toxicity for groups A and B: grade 2=0% and 14%, grade 1=54% and 14%, grade 0=46%
and 72%. GU ﬁgures: grade 2=7% and 14%, grade 1=66% and 29%, grade 0=27% and 57%. In total, after 120 MVCT for group,
the standard deviation of the mean individual patient corrections in anterior–posterior direction was 1.5mm and 2mm. Mean
irradiation time was 520±30 s and 344±96 s. A 25-min time slot is dedicated to every fraction in both groups.
Conclusion. High-dose hypofractionated helical tomotherapy had an acceptable acute toxicity proﬁle in both fractionation
schemes.
http://dx.doi.org/10.1016/j.rpor.2013.03.523
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Introduction. Rectum is an organ at risk to consider in radiotherapy treatments in prostate cancer.
Purpose. To describe the method of placement of a transperineal balloon to minimize the dose that rectum receives.
Methods. Male, 68 years old with prostate cancer T1cN0M0 Gleason 7 (4 + 3), PSA 5.59, diagnosed in March 2010. He was treated
hypofractionated IMRT treatment (70Gy, 2.5Gy/day) in June 2010. In March 2011, a PSA elevation was observed, which was
conﬁrmed over several months to achieved Nadir + 2. A new biopsy and a PET-Choline was request to conﬁrm the existence of
S336 reports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) S309–S336
tumor persistence. It was proposed androgen deprivation therapy, external radiation therapy on node chains with IMRT/IGRT
protecting the maximum rectum and bladder. For tumor persistence brachytherapy treatment was chosen after transperineal
balloon was placed to protect the rectum. This balloon separates the prostate and rectum allowing to radiate prostate tumors
while sparing healthy rectal tissue. The balloon is placed in the prostate-rectum interspace transperineally, guided by transrectal
ultrasound. After this, it is inﬂated with sterile saline to reach its ﬁnal conﬁguration. The balloon implant remains inﬂated during
the whole treatment period and completely biodegrades in the body after six months.
Results. After brachytherapy treatment, it was observed grade 1 urinary acute toxicity and no gastrointestinal toxicity. It has not
been evaluated for chronic toxicity yet.
Conclusions. The biodegradable balloon is a feasible method to separate the prostate and rectum during prostate treatments,
allowing to decrease grade 2 rectal toxicity.
http://dx.doi.org/10.1016/j.rpor.2013.03.524
